Agreed, he had to sell his sharss to avoid any perceived conflict of interest when he took up his new chief scientist posting.
there is one small cap focussed fund manager buying who said in December he had acquired around a third of the stock he wanted in the company.
Substantial blocks of shares here are hard to come by.
Continue to believe that new trials being signed will flow through the sales pipeline into contract wins in 2016 - this is the firs full year of the new strategy of having an effective sales force in place to drive contract wins
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
-0.030(1.74%) |
Mkt cap ! $286.9M | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.72 | $1.68 | $33.63K | 19.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1591 | $1.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.71 | 10000 | 2 |
View Market Depth
| Last trade - 16.10pm 16/07/2025 (20 minute delay) ? |
| CGS (ASX) Chart |